Systemic therapy developments and their effects regarding the current concept of recurrent ovarian carcinoma as a chronic disease

Archives of Gynecology and Obstetrics

Volumn 280, Issue 5, 2009, Pages 719-724

  Güth, Uwe ^a   Kann, Simone Rachel ^a   Huang, Dorothy Jane ^a   Schötzau, Andreas ^b   Holzgreve, Wolfgang ^a   Wight, Edward ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Schotzau and Simmen Institute for Biomathematics   (Switzerland)

Author keywords

Chemotherapy; Chronic disease; Outcome; Ovarian carcinoma; Recurrent disease

Indexed keywords

AFLIBERCEPT; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MELPHALAN; NAVELBINE; PACLITAXEL; TOPOTECAN; TREOSULFAN;

ARTICLE; BRAIN METASTASIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PROGNOSIS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CHRONIC DISEASE; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL;

EID: 70349519212     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-009-0995-2     Document Type: Article

References (16)

1. RM Bukowski RF Ozols M Markman 2007 The management of recurrent ovarian cancer Semin Oncol 34 S1 S15 10.1053/j.seminoncol.2007.03.012 17512352 10.1053/j.seminoncol.2007.03.012 1:CAS:528:DC%2BD2sXntlWmu7k%3D (Pubitemid 46745307)
2. M Markman 2006 Unresolved issues in the chemotherapeutic management of gynecologic malignancies Semin Oncol 33 S33 S38 10.1053/j.seminoncol.2006.03.013 16716801 10.1053/j.seminoncol.2006.03.013 1:CAS:528:DC%2BD28Xms1Siu7k%3D (Pubitemid 43729193)
3. CM Michener JL Belinson 2005 Modern management of recurrent ovarian carcinoma. A systematic approach to a chronic disease Oncology (Williston Park) 19 1277 1285 discussion 1285, 1288, 1293
4. M Fung-Kee-Fung T Oliver L Elit, et al. 2007 Optimal chemotherapy treatment for women with recurrent ovarian cancer Curr Oncol 14 195 208 10.3747/co.2007.148 17938703 10.3747/co.2007.148 1:STN:280: DC%2BD2snhsVGitw%3D%3D
5. TJ Herzog 2006 The current treatment of recurrent ovarian cancer Curr Oncol Rep 8 448 454 10.1007/s11912-006-0074-9 17040623 10.1007/s11912-006-0074-9 1:CAS:528:DC%2BD28Xht1ertbrN (Pubitemid 44697774)
6. SC Modesitt AA Jazaeri 2007 Recurrent epithelial ovarian cancer: pharmacotherapy and novel therapeutics Expert Opin Pharmacother 8 2293 2305 10.1517/14656566.8.14.2293 17927484 10.1517/14656566.8.14.2293 1:CAS:528:DC%2BD2sXhtFeqtrfL (Pubitemid 350001591)
7. Ozols R, Rubin S, Thomas G, Robboy S (2005) Epithelial ovarian cancer. In: Hoskins W, Perez C, Young R et al (eds) Principles and practice of gynecologic oncology, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 895-987
8. RF Ozols 2006 Challenges for chemotherapy in ovarian cancer Ann Oncol 17 Suppl 5 v181 v187 10.1093/annonc/mdj978 16807453 10.1093/annonc/mdj978 (Pubitemid 43994856)
9. Lubkin I, Larsen P (2002) Chronic illness. Jones & Bartlett, Sudbury
10. S Norris R Glasgow M Engelgau, et al. 2003 Chronic disease management: a definition and systematic approach to component interventions Dis Manag Health Outcomes 11 477 488 10.2165/00115677-200311080-00001 10.2165/00115677-200311080- 00001 (Pubitemid 37056112)
11. M Markman 2001 Why study third-, fourth-, fifth-line chemotherapy of ovarian cancer? Gynecol Oncol 83 449 450 10.1006/gyno.2001.6458 11733953 10.1006/gyno.2001.6458 1:STN:280:DC%2BD3MnovVehtw%3D%3D (Pubitemid 33139701)
12. A du Bois M Quinn T Thigpen, et al. 2005 2004 Consensus statements on the management of ovarian cancer: final document of the 3rd international gynecologic cancer intergroup ovarian cancer consensus conference (GCIG OCCC 2004) Ann Oncol 16 Suppl 8 viii7 viii12 16239238 10.1093/annonc/mdi961 (Pubitemid 41631227)
13. MK Parmar JA Ledermann N Colombo, et al. 2003 Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial Lancet 361 2099 2106 10.1016/S0140-6736(03)13718-X 12826431 10.1016/S0140-6736(03)13718-X 1:STN:280:DC%2BD3szhtVGjtQ%3D%3D (Pubitemid 36782252)
14. J Pfisterer M Plante I Vergote, et al. 2006 Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG J Clin Oncol 24 4699 4707 10.1200/JCO.2006.06.0913 16966687 10.1200/JCO.2006.06. 0913 1:CAS:528:DC%2BD28XhtFynsr3O (Pubitemid 46630933)
15. JM Ferrero B Weber JF Geay, et al. 2007 Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial Ann Oncol 18 263 268 10.1093/annonc/mdl376 17108151 10.1093/annonc/mdl376 (Pubitemid 46323091)
16. J Pfisterer JA Ledermann 2006 Management of platinum-sensitive recurrent ovarian cancer Semin Oncol 33 S12 S16 10.1053/j.seminoncol.2006.03.012 16716798 10.1053/j.seminoncol.2006.03.012 1:CAS:528:DC%2BD28Xms1Siu7o%3D (Pubitemid 43744482)